Zosano Pharma Corporation (ZSAN) Is A Buy Stock For Small Caps – Analysts

Zosano Pharma Corporation (NASDAQ:ZSAN) has a beta value of 3.07 and has seen 1.47 million shares traded in the recent trading session. The company, currently valued at $61.00M, closed the recent trade at $0.50 per share which meant it lost $0.0 on the day or -1.25% during that session. The ZSAN stock price is -512.0% off its 52-week high price of $3.06 and 8.0% above the 52-week low of $0.46. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.37 million shares traded. The 3-month trading volume is 2.58 million shares.

The consensus among analysts is that Zosano Pharma Corporation (ZSAN) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Sporting -1.25% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, 01/07/22 when the ZSAN stock price touched $0.50 or saw a rise of 29.45%. Year-to-date, Zosano Pharma Corporation shares have moved 7.45%, while the 5-day performance has seen it change 7.45%. Over the past 30 days, the shares of Zosano Pharma Corporation (NASDAQ:ZSAN) have changed -11.71%. Short interest in the company has seen 4.86 million shares shorted with days to cover at 1.44.

Wall Street analysts have a consensus price target for the stock at $2.00, which means that the shares’ value could jump 75.0% from the levels at last check today. The projected low price target is $2.00 while the price target rests at a high of $2.00. In that case, then, we find that the latest price level in today’s session is -300.0% off the targeted high while a plunge would see the stock gain -300.0% from the levels at last check today.

Zosano Pharma Corporation (ZSAN) estimates and forecasts

Figures show that Zosano Pharma Corporation shares have outperformed across the wider relevant industry. The company’s shares have lost -40.31% over the past 6 months, with this year growth rate of 42.86%, compared to 7.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 37.50% and 12.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 717.00%.

3 analysts offering their estimates for the company have set an average revenue estimate of $1.1 million for the current quarter. 2 have an estimated revenue figure of $250k for the next quarter concluding in Mar 2022.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 60.30% over the past 5 years.

ZSAN Dividends

Zosano Pharma Corporation is expected to release its next earnings report between March 09 and March 14 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Zosano Pharma Corporation (NASDAQ:ZSAN)’s Major holders

Insiders own 0.48% of the company shares, while shares held by institutions stand at 10.94% with a share float percentage of 10.99%. Investors are also buoyed by the number of investors in a company, with Zosano Pharma Corporation having a total of 35 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 4.32 million shares worth more than $3.11 million. As of Sep 29, 2021, Vanguard Group, Inc. (The) held 3.65% of shares outstanding.

The other major institutional holder is Aisling Capital Management LP, with the holding of over 2.72 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $1.96 million and represent 2.30% of shares outstanding.

>> 7 Top Picks for the Post-Pandemic Economy <<

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 29, 2021, the former fund manager holds about 2.17% shares in the company for having 2.57 million shares of worth $1.85 million while later fund manager owns 1.49 million shares of worth $1.07 million as of Sep 29, 2021, which makes it owner of about 1.26% of company’s outstanding stock.